Sudden increase in floaters, light flashes, or curtain-like vision loss may signal an eye emergency requiring prompt retinal ...

A school project prompted 17-year-old Edward Kang to develop an AI tool that may lead to earlier diagnoses of the disorders.

The 4TAZPower study will follow participants with Barth syndrome for 72 weeks to assess the efficacy and safety.

Chief Medical Officer Hendrik Scholl said the company is advancing its lead compound, Tinlarebant, as a potential treatment ...

Scientists have found out how a person develops acute central vision before birth. It turned out that the interaction of a ...

Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients ...

Drivers have been told that if they do not act correctly, they could face serious consequences ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

"We will grow into a partner-type API company equipped with global-standard production infrastructure, based on quality and ...

This medical stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue forecast in its latest ...

Key Points Interested in Ocugen, Inc.? Here are five stocks we like better. Ocugen plans three late-stage retinal gene ...

Detailed price information for Aldeyra Therapeu (ALDX-Q) from The Globe and Mail including charting and trades.